Diebold Nixdorf, Incorporated (DBD) Stock Forecast
DBD analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.67 / 5 from 3 analysts
- Price target
- $98.33 average of analyst targets
- Upside to target
- +47.1% from the latest close
- Next earnings
- October 28, 2026 EPS estimate $1.38
- 52-week range
- $56.24 – $90.75
DBD analyst ratings
3 analystsNumber of analysts at each rating.
DBD price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
DBD earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $1.31 | $1.16 | $1.49 | $1.38 | −5.3% | 3 |
| Current fiscal year (2026) | $5.37 | $5.20 | $5.52 | $4.73 | +13.6% | 3 |
| Next fiscal year (2027) | $7.02 | $6.45 | $8.11 | $5.37 | +30.6% | 3 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
DBD revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $971.7M | $956.9M | $983.0M | +2.8% | 3 |
| Current fiscal year (2026) | $3.91B | $3.90B | $3.91B | +2.6% | 3 |
| Next fiscal year (2027) | $4.02B | $3.99B | $4.07B | +3.0% | 3 |
DBD EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
DBD revenue: reported and forecast
DBD EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $1.45 | $1.31 | $1.31 | $1.31 | $1.31 | −10.1% | 1 up · 2 down |
| Current fiscal year (2026) | $5.49 | $5.37 | $5.37 | $5.37 | $5.37 | −2.1% | 1 up · 2 down |
| Next fiscal year (2027) | $6.79 | $7.02 | $7.02 | $7.02 | $7.02 | +3.3% | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
DBD earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; DBD beat in 8 of 12.
What analysts expect from DBD
3 analysts cover Diebold Nixdorf; their consensus rating is strong buy (4.67 on a 1–5 scale, where 5 is a strong buy). The average price target is $98.33, 47.1% above the latest close of $66.83. Analysts expect earnings of $5.37 per share for 2026, +13.6% from a year earlier. For 2027 the average estimate is $7.02 per share on revenue of $4.0 billion. Diebold Nixdorf beat the EPS estimate in 8 of the last 12 quarters.
Related: DBD income statement, DBD key metrics, DBD chart. See the DBD stock overview for the latest quote and news.
DBD forecast FAQ
What is Diebold Nixdorf's price target?
The average analyst price target for Diebold Nixdorf is $98.33, 47.1% above the latest close of $66.83.
Is Diebold Nixdorf a buy, hold or sell?
Of 3 analysts covering Diebold Nixdorf, 2 rate it a strong buy, 1 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Diebold Nixdorf's EPS forecast?
Analysts forecast $5.37 per share for 2026 (range $5.20 to $5.52); for 2027 the estimate is $7.02.
What is Diebold Nixdorf's revenue forecast?
The average revenue estimate for 2026 is $3.9 billion, growth of 2.6%; for 2027 it is $4.0 billion.
When does Diebold Nixdorf report earnings?
Diebold Nixdorf is expected to report results for the quarter ending September 30, 2026 on October 28, 2026 before the market opens; the EPS estimate is $1.38.
Does Diebold Nixdorf usually beat earnings estimates?
Diebold Nixdorf reported EPS at or above the analyst estimate in 8 of the last 12 quarters.